Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

MLA

Nagler, Arnon, et al. “Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post-Transplant Cyclophosphamide (PTCy). A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.” Bone Marrow Transplantation, vol. 58, no. 5, May 2023, pp. 552–57. EBSCOhost, https://doi.org/10.1038/s41409-023-01940-6.

APA

Nagler, A., Labopin, M., Swoboda, R., Kulagin, A., Labussière-Wallet, H., Rovira, M., Blaise, D., Vydra, J., Yakoub-Agha, I., Choi, G., Reményi, P., Koc, Y., Sanz, J., Ciceri, F., & Mohty, M. (2023). Allogeneic stem cell transplantation for patients with acute myeloid leukemia (AML) in second complete remission (CR2) transplanted from unrelated donors with post-transplant cyclophosphamide (PTCy). A study on behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Bone Marrow Transplantation, 58(5), 552–557. https://doi.org/10.1038/s41409-023-01940-6

Chicago

Nagler, Arnon, Myriam Labopin, Ryszard Swoboda, Alexander Kulagin, Hélène Labussière-Wallet, Montserrat Rovira, Didier Blaise, et al. 2023. “Allogeneic Stem Cell Transplantation for Patients with Acute Myeloid Leukemia (AML) in Second Complete Remission (CR2) Transplanted from Unrelated Donors with Post-Transplant Cyclophosphamide (PTCy). A Study on Behalf of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.” Bone Marrow Transplantation 58 (5): 552–57. doi:10.1038/s41409-023-01940-6.